NCT01935921View on ClinicalTrials.gov

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 9, 2013

Primary Completion Date

October 29, 2016

Study Completion Date

July 6, 2018

Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
BIOLOGICAL

Cetuximab

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01935921 - Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | Biotech Hunter | Biotech Hunter